3 completed, 1 recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Recruiting 1 |
Follow Sparrow Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) clofutriben, Placebo - Type 2 Diabetes, Cortisol Excess | Phase 2 | Recruiting | Sparrow Pharmaceuticals | 1500 | 2025-11-29 | 2026-10-06 |
| SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor SPI-62 dose - Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome | Phase 2 | Completed | Sparrow Pharmaceuticals | 30 | 2023-07-01 | 2026-02-13 |
| SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome SPI-62, Placebo - Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion | Phase 2 | Completed | Sparrow Pharmaceuticals | 26 | 2022-09-01 | 2025-10-08 |
| A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR) SPI-62, SPI-62 matched placebo, Prednisolone 10mg - Polymyalgia Rheumatica | Phase 2 | Completed | Sparrow Pharmaceuticals | 66 | 2022-07-22 | 2025-05-11 |
ACTH Syndrome, Ectopic (2) · Cushing Syndrome (2) · Acth-Independent Macronodular Adrenal Hyperplasia (1) · Diabetes Mellitus, Type 2 (1) · Pituitary ACTH Hypersecretion (1) · Polymyalgia Rheumatica (1)
ASP3662 (1) · Prednisolone (1)
United States (3) · Romania (2) · Bulgaria (1) · Germany (1) · Poland (1) · United Kingdom (1)
Frank Czerwiec, MD (2) · David Katz (1)